1. Light-based gamma entrainment with novel invisible spectral flicker stimuli.
- Author
-
Hansen LS, Carstensen MH, Henney MA, Nguyen NM, Thorning-Schmidt MW, Broeng J, Petersen PM, and Andersen TS
- Subjects
- Humans, Male, Female, Adult, Light, Alzheimer Disease physiopathology, Young Adult, Electroencephalography, Gamma Rhythm physiology, Evoked Potentials, Visual physiology, Photic Stimulation methods
- Abstract
Light-based gamma entrainment using sensory stimuli (GENUS) shows considerable potential for the treatment of Alzheimer's disease (AD) in both animal and human models. While the clinical efficacy of GENUS for AD is paramount, its effectiveness will eventually also rely on the barrier to treatment adherence imposed by the discomfort of gazing at luminance flickering (LF) light. Currently, there have been few attempts to improve the comfort of GENUS. Here we investigate if Invisible spectral flicker (ISF), a novel type of light-based 40 Hz GENUS for which the flicker is almost imperceptible, can be used as a more comfortable option. We found that whereas ISF, LF, and chromatic flicker (CF) all produce a 40 Hz steady-state visually evoked potential (SSVEP), ISF scores significantly better on measures of comfort and perceived flicker. We also demonstrate that, while there is a trend towards a lower SSVEP response, reducing the stimulation brightness has no significant effect on the 40 Hz SSVEP or perceived flicker, though it significantly improves comfort. Finally, there is a slight decrease in the 40 Hz SSVEP response when stimulating with ISF from increasingly peripheral angles. This may ease the discomfort of GENUS treatment by freeing patients from gazing directly at the light., Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Additional information: The initiators of this project are TSA and PMP. The project has not received any funding. TSA declares that he has no conflict of interest. PMP owns shares in the company OptoCeutics ApS. MHC is CTO and owns shares in the company OptoCeutics ApS. LSH is a full-time employee of OptoCeutics ApS, but initiated the work while at DTU Photonics. MAH is an industrial Ph.D. student enrolled at DTU Compute and partially funded by OptoCeutics ApS and the Innovation Fund Denmark (Case number: 1044-00177A). Both LSH and MAH have stock options in the company OptoCeutics ApS. MTS had a student research position at OptoCeutics ApS, however, he conducted his work while being a Master’s student at DTU. NMN is CEO and owns shares in the company OptoCeutics ApS. JEB owns shares in the company OptoCeutics ApS., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF